1
|
Sharma J, Deo SVS, Kumar S, Barwad AW, Rastogi S, Sharma DN, Singh G, Bhoriwal S, Mishra A, K R, Saikia J, Mandal A, Bansal B, Gaur M. Clinicopathological Profile and Survival Outcomes in Patients with Localised Extremity Synovial Sarcomas. Clin Oncol (R Coll Radiol) 2024; 36:e97-e104. [PMID: 38326122 DOI: 10.1016/j.clon.2024.01.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 12/11/2023] [Accepted: 01/26/2024] [Indexed: 02/09/2024]
Abstract
AIMS Synovial sarcoma is a rare but aggressive variant of soft-tissue sarcoma. Literature is sparse and reported mostly from the West. We analysed the clinical profiles and prognostic factors of extremity synovial sarcoma patients in order to study their clinical journey. MATERIALS AND METHODS This was a retrospective analysis. All patients with extremity synovial sarcoma treated between 1992 and 2020 were included. Patients with metastases at presentation were excluded. A descriptive analysis of demographic and clinicopathological features of patients undergoing limb salvage surgery (LSS) or amputation was carried out. Overall survival and disease-free survival were calculated for the entire cohort as well as for the LSS and amputation groups. Factors prognostic for survival were identified. RESULTS In total, 157 patients had localised extremity synovial sarcoma. Predominantly, young adults (median 31 years) and males (61%) were affected. Over 70% of patients presented after recurrence or unplanned surgeries. Sixty-seven per cent of tumours were >5 cm, 69% were deep and 23% involved bone. The limb salvage rate was 64%. In the LSS group, adjuvant radiotherapy and chemotherapy were given to 72% and 68% of patients, respectively. In the amputation group, 72% of patients received adjuvant chemotherapy. In a median follow-up of 59 months, 39.4% of patients had recurrences, the majority (61.2%) were systemic. Five-year overall survival and disease-free survival were 53.4% and 49.8%, respectively. Overall survival was 63.9% and 29.7% in the LSS and amputation groups, respectively. On multivariate analysis, tumour size, depth, omission of radiotherapy and bone invasion were found to be the adverse prognostic factors. CONCLUSION This is one of the largest studies on extremity synovial sarcoma. Mostly males and young adults were affected. The limb salvage rate was 64%, despite most being referred after unplanned surgery. Almost 70% of patients received radiotherapy and chemotherapy. Overall survival was inferior in the amputation group. Tumour size >5 cm, depth and bone invasion were negative, whereas adjuvant radiotherapy was a positive prognostic factor for survival. Chemotherapy had no impact on survival.
Collapse
Affiliation(s)
- J Sharma
- Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India.
| | - S V S Deo
- Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India
| | - S Kumar
- Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India
| | - A W Barwad
- Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
| | - S Rastogi
- Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India
| | - D N Sharma
- Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
| | - G Singh
- Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India
| | - S Bhoriwal
- Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India
| | - A Mishra
- Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India
| | - R K
- Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India
| | - J Saikia
- Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India
| | - A Mandal
- Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India
| | - B Bansal
- Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India
| | - M Gaur
- Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India
| |
Collapse
|
2
|
Shukla S, Karbhari A, Rastogi S, Agarwal U, Rai P, Mahajan A. Bench-to-bedside imaging in brain metastases: a road to precision oncology. Clin Radiol 2024:S0009-9260(24)00137-5. [PMID: 38637186 DOI: 10.1016/j.crad.2024.02.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Revised: 02/08/2024] [Accepted: 02/12/2024] [Indexed: 04/20/2024]
Abstract
Radiology has seen tremendous evolution in the last few decades. At the same time, oncology has made great strides in diagnosing and treating cancer. Distant metastases of neoplasms are being encountered more often in light of longer patient survival due to better therapeutic strategies and diagnostic methods. Brain metastasis (BM) is a dismal manifestation of systemic cancer. In the present scenario, magnetic resonance imaging (MRI), computed tomography (CT) and positron emission tomography (PET) are playing a big role in providing molecular information about cancer. Lately, molecular imaging has emerged as a stirring arena of dynamic imaging techniques that have enabled clinicians and scientists to noninvasively visualize and understand biological processes at the cellular and molecular levels. This knowledge has impacted etiopathogenesis, detection, personalized treatment, drug development, and our understanding of carcinogenesis. This article offers insight into the molecular biology underlying brain metastasis, its pathogenesis, imaging protocols, and algorithms. It also discusses disease-specific molecular imaging features, focusing on common tumors that spread to the brain, such as lung, breast, colorectal cancer, melanoma, and renal cell carcinoma. Additionally, it covers various targeted treatment options, criteria for assessing treatment response, and the role of artificial intelligence in diagnosing, managing, and predicting prognosis for patients with brain metastases.
Collapse
Affiliation(s)
- S Shukla
- Department of Radiodiagnosis and Imaging, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Hospital, Varanasi, 221 005, Maharashtra, India; Department of Radiodiagnosis and Imaging, Homi Bhabha National Institute, Tata Memorial Hospital, Mumbai, 400 012, Maharashtra, India
| | - A Karbhari
- Department of Radiodiagnosis and Imaging, Homi Bhabha National Institute, Tata Memorial Hospital, Mumbai, 400 012, Maharashtra, India
| | - S Rastogi
- Department of Radiodiagnosis and Imaging, Homi Bhabha National Institute, Tata Memorial Hospital, Mumbai, 400 012, Maharashtra, India
| | - U Agarwal
- Department of Radiodiagnosis and Imaging, Homi Bhabha National Institute, Tata Memorial Hospital, Mumbai, 400 012, Maharashtra, India
| | - P Rai
- Department of Radiodiagnosis and Imaging, Homi Bhabha National Institute, Tata Memorial Hospital, Mumbai, 400 012, Maharashtra, India
| | - A Mahajan
- Department of Imaging, The Clatterbridge Cancer Centre NHS Foundation Trust, L7 8YA Liverpool, UK; Faculty of Health and Life Sciences, University of Liverpool, L7 8TX, Liverpool, UK.
| |
Collapse
|
3
|
Bhattacharya K, Rastogi S, Mahajan A. Post-treatment imaging of gliomas: challenging the existing dogmas. Clin Radiol 2024; 79:e376-e392. [PMID: 38123395 DOI: 10.1016/j.crad.2023.11.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Revised: 10/23/2023] [Accepted: 11/21/2023] [Indexed: 12/23/2023]
Abstract
Gliomas are the commonest malignant central nervous system tumours in adults and imaging is the cornerstone of diagnosis, treatment, and post-treatment follow-up of these patients. With the ever-evolving treatment strategies post-treatment imaging and interpretation in glioma remains challenging, more so with the advent of anti-angiogenic drugs and immunotherapy, which can significantly alter the appearance in this setting, thus making interpretation of routine imaging findings such as contrast enhancement, oedema, and mass effect difficult to interpret. This review details the various methods of management of glioma including the upcoming novel therapies and their impact on imaging findings, with a comprehensive description of the imaging findings in conventional and advanced imaging techniques. A systematic appraisal for the existing and emerging techniques of imaging in these settings and their clinical application including various response assessment guidelines and artificial intelligence based response assessment will also be discussed.
Collapse
Affiliation(s)
- K Bhattacharya
- Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - S Rastogi
- Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - A Mahajan
- Department of imaging, The Clatterbridge Cancer Centre, NHS Foundation Trust, Pembroke Place, Liverpool L7 8YA, UK; University of Liverpool, Liverpool L69 3BX, UK.
| |
Collapse
|
4
|
Serrano C, Rothschild S, Villacampa G, Heinrich MC, George S, Blay JY, Sicklick JK, Schwartz GK, Rastogi S, Jones RL, Rutkowski P, Somaiah N, Navarro V, Evans D, Trent JC. Novel trial designs for patients with gastrointestinal stromal tumor. ESMO Open 2024; 9:102218. [PMID: 38194880 PMCID: PMC10837772 DOI: 10.1016/j.esmoop.2023.102218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2023] [Accepted: 12/09/2023] [Indexed: 01/11/2024] Open
Affiliation(s)
- C Serrano
- Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona; Sarcoma Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
| | | | - G Villacampa
- Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; The Institute of Cancer Research, London, UK
| | - M C Heinrich
- Portland VA Health Care System and Knight Cancer Institute, Oregon Health & Science University, Portland
| | - S George
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - J-Y Blay
- Department of Medical Oncology, Centre Léon Bérard, Lyon; Université Claude Bernard, Lyon, France
| | - J K Sicklick
- Department of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego; Department of Pharmacology, University of California San Diego, San Diego
| | - G K Schwartz
- Case Comprehensive Cancer Center, Cleveland, USA
| | - S Rastogi
- Department of Medical Oncology, AIIMS, New Delhi, India
| | - R L Jones
- The Royal Marsden NHS Foundation Trust, London; Division of Clinical Studies, The Institute of Cancer Research, London, UK
| | - P Rutkowski
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - N Somaiah
- Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston
| | - V Navarro
- Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - D Evans
- The Life Raft Group, Wayne, USA
| | - J C Trent
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, USA
| |
Collapse
|
5
|
Rastogi S, Fernandes S, Sasi N, Kashyap D, Tansir G, Kumar A, Gamangati S, Barwad A, Ahmed Shamim S. 127P Outcomes of advanced chordoma from dedicated sarcoma medical oncology clinic from a tertiary care center in North India. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.101073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
6
|
Tansir G, Rastogi S, Fernandes S, Ahmed Shamim S, Dhamija E, Barwad A, Pandey R. 76P Thoracic synovial sarcoma: A single-center, real-world analysis of treatment paradigms and clinical outcomes. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.101113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
7
|
Kumar S, Rastogi S, Jadon A. A Prospective Randomised study to evaluate the efficacy of Propofol-Ketamine (Ketofol ) and dexmedetomidine for performing Drug Induced Sleep Endoscopy (DISE) in patients of Obstructive Sleep Apnea. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
8
|
Santhosh A, Rastogi S, Ahmed Shamim S, Yadav R, Barwad A, dash N. 455P Succinate dehydrogenase deficient GIST: Case series and review of literature from a tertiary care centre in India. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
9
|
Tansir G, Rastogi S, Dubasi S, Lavu R, Chitikela S, Barwad A, Goyal A. 414P Lessons learnt from clinico-genomic profiling of families with Li Fraumeni Syndrome: The largest case series from the Indian setting. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
10
|
Praveen D, Shyam G, Pareek V, Shishak S, Barthwal M, Pandey S, Nirala S, Sanyal S, Pattanaik J, Samala S, Tanwar M, Mandal S, A A, Bora D, Ravi A, Ghosh V, Solanki A, Sisodiya R, Dhamija E, Rastogi S, Barwad A, Sharma D, Pandey R. PO-1437 Clinical outcomes in adult primitive neuro-ectodermal tumor of kidney: A single institute experience. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03401-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Rastogi S, Chanchani P, Sankaran M, Warrier R. Grasslands half‐full: investigating drivers of spatial heterogeneity in ungulate occurrence in Indian Terai. J Zool (1987) 2021. [DOI: 10.1111/jzo.12939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- S. Rastogi
- Post‐Graduate Program in Wildlife Biology and Conservation National Centre for Biological Sciences Bangalore Karnataka India
| | - P. Chanchani
- World Wide Fund for Nature (WWF) New Delhi India
| | - M. Sankaran
- Ecology and Evolution National Centre for Biological Sciences Bangalore Karnataka India
- School of Biology University of Leeds Leeds UK
| | - R. Warrier
- School of Global Environmental Sustainability Colorado State University Fort Collins Colorado USA
| |
Collapse
|
12
|
Chikkabyrappa SM, Chaudhary N, Agarwal A, Rastogi D, Filipov P, Rastogi S. Outcomes among preterm infants with patent ductus arteriosus: Relationship with treatment, gestational age, hemodynamic status and timing of treatment. J Neonatal Perinatal Med 2021; 15:219-227. [PMID: 34719442 DOI: 10.3233/npm-210814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND There remains controversy regarding the outcomes resulting from treatment versus conservative management of patent ductus arteriosus (PDA) among preterm infants. The effects of extreme prematurity, hemodynamic status of the PDA, and age at treatment remain poorly defined. STUDY DESIGN This retrospective case-control study including infants < 1250 gm who were categorized into 3 groups: Group 1: without PDA, Group 2: with untreated PDA, and Group 3: treated PDA. Diagnosis and treatment of PDA extracted from the medical records. Demographics, clinical characteristics, and outcomes compared using chi-square and analysis of variance. Logistic regression used to estimate adjusted odds ratios. RESULTS The study included 734 infants, with 141(19%) in Group 1, 329 (45%) in 2, and 264 (36%) in 3. Group 3 had higher incidence of bronchopulmonary dysplasia (BPD) (aOR, 2.9; 95%CI 1.7-4.8). Infant treated for hemodynamically significant PDA (HSPDA) had higher incidence of BPD (aOR, 1.9; 95%CI 1.0-3.8) and retinopathy of prematurity (ROP) (aOR, 3.4; 95%CI 1.6-6.9). There were no differences in outcome associated with treatment among≤26 weeks gestation and the age when treated. CONCLUSION Infants with PDA who were treated had higher incidence of BPD. Among those who were treated, those with HSPDA had a higher incidence of BPD and ROP.
Collapse
Affiliation(s)
| | - N Chaudhary
- Beth Israel Deaconess Medical Center, Harvard University, Boston, MA
| | - A Agarwal
- The Children's Hospital of San Antonio, Baylor College of Medicine, San Antonio, TX
| | - D Rastogi
- Children's National Hospital, George Washington University, Washington, DC
| | - P Filipov
- Maimonides Medical Center, Brooklyn, NY
| | - S Rastogi
- Children's National Hospital, George Washington University, Washington, DC
| |
Collapse
|
13
|
Dwivedi M, Powali S, Rastogi S, Singh A, Gupta DK. Microbial community in human gut: a therapeutic prospect and implication in health and diseases. Lett Appl Microbiol 2021; 73:553-568. [PMID: 34365651 DOI: 10.1111/lam.13549] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2021] [Revised: 07/30/2021] [Accepted: 08/03/2021] [Indexed: 12/14/2022]
Abstract
The interest in the working and functionality of the human gut microbiome has increased drastically over the years. Though the existence of gut microbes has long been speculated for long over the last few decades, a lot of research has sprung up in studying and understanding the role of gut microbes in the human digestive tract. The microbes present in the gut are highly instrumental in maintaining the metabolism in the body. Further research is going on in this field to understand how gut microbes can be employed as potential sources of novel therapeutics; moreover, probiotics have also elucidated their significant place in this direction. As regards the clinical perspective, microbes can be engineered to afford defence mechanisms while interacting with foreign pathogenic bodies. More investigations in this field may assist us to evaluate and understand how these cells communicate with human cells and promote immune interactions. Here we elaborate on the possible implication of human gut microbiota into the immune system as well as explore the probiotics in the various human ailments. Comprehensive information on the human gut microbiome at the same platform may contribute effectively to our understanding of the human microbiome and possible mechanisms of associated human diseases.
Collapse
Affiliation(s)
- M Dwivedi
- Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, India
| | - S Powali
- Maulana Abdul Kalam Azad University of Technology, Kolkatta, India
| | - S Rastogi
- Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, India
| | - A Singh
- Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, India
| | - D K Gupta
- Department of Biochemistry, University of Allahabad, Prayagraj, India
| |
Collapse
|
14
|
Brahmbhatt HD, Gupta R, Gupta A, Rastogi S, Misri R, Mobeen A, Ghosh A, Kothari P, Sitaniya S, Scaria V, Singh A. The long noncoding RNA MALAT1 suppresses miR-211 to confer protection from ultraviolet-mediated DNA damage in vitiligo epidermis by upregulating sirtuin 1. Br J Dermatol 2020; 184:1132-1142. [PMID: 33152110 DOI: 10.1111/bjd.19666] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/31/2020] [Indexed: 12/15/2022]
Abstract
BACKGROUND The absence of melanocytes poses a challenge for long-term tissue homeostasis in vitiligo. Surprisingly, while individuals with Fitzpatrick phototypes I-II (low melanin content) have a higher incidence of melanoma and nonmelanoma skin cancer, people with vitiligo are at a decreased risk for the same. OBJECTIVES To understand the molecular mechanisms that protect vitiligo skin from ultraviolet (UV)-induced DNA damage by (i) characterizing differentially expressed microRNAs in lesional vs. nonlesional epidermis and (ii) identifying their upstream regulators and downstream gene targets. METHODS Genome-wide microRNA profiling of nonlesional and lesional epidermis was performed on five individuals with stable nonsegmental vitiligo using next-generation RNA sequencing. The relevance of the upstream regulator and downstream target gene of the most differentially expressed microRNA was studied. RESULTS Our study found sirtuin1 (SIRT1), an NAD-dependent deacetylase, to be a direct target of miR-211 - the most significantly downregulated microRNA in lesional epidermis. Inhibition of SIRT1 with EX-527 downregulated keratin 10 and involucrin, suggesting that SIRT1 promotes keratinocyte differentiation. Overexpression of miR-211 mimic led to a significant increase in γ-H2AX positivity and cyclobutane pyrimidine dimer (CPD) formation, hallmarks of UVB-mediated DNA damage. These effects could be ameliorated by the addition of resveratrol, a SIRT1 activator. Furthermore, a long noncoding RNA, MALAT1, was identified as a negative upstream regulator of miR-211. Overexpression of MALAT1 resulted in increased expression of SIRT1 and a concomitant removal of UVB-induced CPDs in primary keratinocytes. CONCLUSIONS These findings establish a novel MALAT1-miR-211-SIRT1 signalling axis that potentially confers protection to the 'amelanotic' keratinocytes in vitiligo.
Collapse
Affiliation(s)
- H D Brahmbhatt
- CSIR-Institute of Genomics and Integrative Biology, Mathura Road, New Delhi, 110025, India.,Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - R Gupta
- CSIR-Institute of Genomics and Integrative Biology, Mathura Road, New Delhi, 110025, India.,Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - A Gupta
- D.Y. Patil Medical College, Dr D.Y. Patil University, Pimpri, Pune, Maharashtra, 411018, India
| | - S Rastogi
- CSIR-Institute of Genomics and Integrative Biology, Mathura Road, New Delhi, 110025, India
| | - R Misri
- Hindu Rao Hospital, New Delhi, India
| | - A Mobeen
- CSIR-Institute of Genomics and Integrative Biology, Mathura Road, New Delhi, 110025, India.,Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - A Ghosh
- CSIR-Institute of Genomics and Integrative Biology, Mathura Road, New Delhi, 110025, India.,Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - P Kothari
- D.Y. Patil Medical College, Dr D.Y. Patil University, Pimpri, Pune, Maharashtra, 411018, India
| | - S Sitaniya
- D.Y. Patil Medical College, Dr D.Y. Patil University, Pimpri, Pune, Maharashtra, 411018, India
| | - V Scaria
- CSIR-Institute of Genomics and Integrative Biology, Mathura Road, New Delhi, 110025, India.,Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - A Singh
- CSIR-Institute of Genomics and Integrative Biology, Mathura Road, New Delhi, 110025, India.,Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| |
Collapse
|
15
|
Pant S, Dimri A, Arora R, Bachani S, Raisuddin S, Siraj F, Rastogi S. Chlamydia trachomatis infection predisposes to ectopic pregnancy by regulating expression of tetraspanins in fallopian tube: A pilot study. Int J Infect Dis 2020. [DOI: 10.1016/j.ijid.2020.09.1171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
16
|
Singh N, Prasad P, Das B, Rastogi S. Is there an association between Chlamydia trachomatis load and in situ expression of cyclooxygenase/inflammatory cytokines in first trimester aborters. Int J Infect Dis 2020. [DOI: 10.1016/j.ijid.2020.09.1167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
17
|
Dimri A, Pant S, Arora R, Bachani S, Parvez S, Siraj F, Rastogi S. Differential expression of Chlamydia trachomatis heat shock protein 60-encoding genes in tubal ectopic pregnancy. Int J Infect Dis 2020. [DOI: 10.1016/j.ijid.2020.09.1166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
18
|
Kumar P, Bhakuni D, Khanna G, Rastogi S. Screening of anti-Chlamydia trachomatis antibodies in reactive arthritis/undifferentiated spondyloarthropathy patients: A prospective study from India. Int J Infect Dis 2020. [DOI: 10.1016/j.ijid.2020.09.1165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
19
|
Abstract
OBJECTIVE The study explored the chemoprophylactic potential of roflumilast against 1,2-dimethylhydrazine (DMH) actuated preneoplastic colon damage in albino Wistar rats. METHODS Animals were arbitrarily divided into five groups of six animals each. DMH was used to induce preneoplastic colon damage (20 mg/kg/7 days, subcutaneously, for 42 days). Roflumilast was administered subcutaneously at two doses (1 and 5 mg/kg/day, from day 28 to 42). At the end of the study, the animals were recorded for the electrocardiographic changes and heart rate variability (HRV) paradigms on 42nd day, using PowerLab system. Blood samples were collected from all the animals to measure hydrogen sulfide (H2S) and nitric acid. The colon tissue was dissected out and analyzed for inflammatory markers, biochemical parameters including, superoxide dismutase, thiobarbituric acid reactive substances, catalase, and glutathione reductase and histopathology. RESULTS DMH caused derangement of HRV factors, abnormal antioxidant markers, and elevated levels of inflammatory markers. H2S and nitric oxide levels upsurge in DMH-treated rats and promoted preneoplastic damage. Histopathologically, loss of crypts, goblet cells, and distorted lamina propria were observed in toxic group. Treatment with roflumilast was able to curtail down oxidative stress and inflammatory markers and stabilitate the hemodynamic derangements as well as was able to restore the normal architecture of colonic mucosa. CONCLUSION The findings from the present study conclude that treatment with roflumilast positively modulates the preneoplastic colon damage.
Collapse
Affiliation(s)
- A S Saeedan
- Department of Pharmacology and Toxicology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Kingdom of Saudi Arabia
| | - S Rastogi
- Department of Pharmaceutical Sciences, School of Biosciences and Biotechnology, Babasaheb Bhimrao Ambedkar University (A Central University), Lucknow, Uttar Pradesh, India
| | - M N Ansari
- Department of Pharmacology and Toxicology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Kingdom of Saudi Arabia
| |
Collapse
|
20
|
Lee H, Patel K, Singam V, Rastogi S, Silverberg J. A study into the risk of serious infections in people with hidradenitis suppurativa. Br J Dermatol 2020. [DOI: 10.1111/bjd.18752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Lee H, Patel K, Singam V, Rastogi S, Silverberg J. 一项关于化脓性汗腺炎患者发生严重感染风险的研究. Br J Dermatol 2020. [DOI: 10.1111/bjd.18767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
22
|
Shishak S, Rastogi S, Pandey R, Barwad A, Dhamija E, Aggarwal A, Kalra K, Shamim S, Parisa M. Malignant melanoma: A study of clinical profiles and treatment outcomes in Indian patients. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz429.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
23
|
Pawar S, Rastogi S, Dhamija E, Barwad A, Kumar V, Pandey R, Shishak S, Kalra K, Aggarwal A, Garg A, Mridha A, Chaubey J, Khan S. Lessons learnt from treatment of foot sarcomas: Analysis from dedicated sarcoma clinic in North India. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz433.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Patel K, Rastogi S, Singam V, Lee H, Amin A, Silverberg J. HS和精神病住院治疗之间的相关性. Br J Dermatol 2019. [DOI: 10.1111/bjd.18193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
25
|
Patel K, Rastogi S, Singam V, Lee H, Amin A, Silverberg J. Association between HS and hospitalization for psychiatric disorders. Br J Dermatol 2019. [DOI: 10.1111/bjd.18183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
26
|
Lee H, Patel K, Singam V, Rastogi S, Silverberg J. Associations of cutaneous and extracutaneous infections with hidradenitis suppurativa in U.S. children and adults. Br J Dermatol 2019; 182:327-334. [DOI: 10.1111/bjd.18093] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/30/2019] [Indexed: 12/29/2022]
Affiliation(s)
- H.H. Lee
- Department of Dermatology Suite 1600, 676 N St Clair St, Northwestern University Feinberg School of Medicine Chicago IL 60611 U.S.A
| | - K.R. Patel
- Department of Dermatology Suite 1600, 676 N St Clair St, Northwestern University Feinberg School of Medicine Chicago IL 60611 U.S.A
| | - V. Singam
- Department of Dermatology Suite 1600, 676 N St Clair St, Northwestern University Feinberg School of Medicine Chicago IL 60611 U.S.A
| | - S. Rastogi
- Department of Dermatology Suite 1600, 676 N St Clair St, Northwestern University Feinberg School of Medicine Chicago IL 60611 U.S.A
| | - J.I. Silverberg
- Department of Dermatology Suite 1600, 676 N St Clair St, Northwestern University Feinberg School of Medicine Chicago IL 60611 U.S.A
- Department of Dermatology, Preventive Medicine and Medical Social Sciences Northwestern University Feinberg School of Medicine Chicago IL U.S.A
- Northwestern Medicine Multidisciplinary Eczema Center Chicago IL U.S.A
| |
Collapse
|
27
|
Rastogi S, Sadowsky L, Thiede R, Erickson T, Hua T, Kosche C, Rastogi A, Patel K, Miller C, Schlosser B. 596 Global sex differences in initial treatment for genital extramammary Paget’s disease: a systematic review. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
28
|
Rastogi S, Shastry J, Kong B, Park J, Patel K, Hua T, Singam V, Lee H, Fuertes E, Silverberg J. 183 Association of atopic dermatitis, ultraviolet radiation and climate factors: a systematic review and ecological meta-analysis. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
29
|
Patel K, Lee H, Rastogi S, Vakharia P, Hua T, Chhiba K, Singam V, Silverberg J. 219 A systematic review and meta-analysis of the association between hidradenitis suppurativa, depression, suicidal ideation, and anxiety. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
30
|
McMichael A, Desai SR, Qureshi A, Rastogi S, Alexis AF. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials. Am J Clin Dermatol 2019; 20:267-276. [PMID: 30471012 DOI: 10.1007/s40257-018-0408-z] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND Data on treatment outcomes in patients with psoriasis who have skin of color are limited. Brodalumab has shown efficacy in patients with moderate-to-severe plaque psoriasis. OBJECTIVE Our objective was to evaluate the efficacy, safety, and health-related quality of life associated with brodalumab in patients with skin of color participating in two phase III, multicenter, randomized, double-blind, placebo- and active comparator-controlled studies (AMAGINE-2/-3). METHODS Patients were self-categorized into racial subgroups (black, Asian, or white) or the non-mutually exclusive ethnic subgroup Hispanic/Latino. Patients were randomized to receive brodalumab 210 mg every 2 weeks (Q2W) or ustekinumab (45 mg in patients weighing ≤ 100 kg and 90 mg in patients weighing > 100 kg) for 52 weeks. Skin clearance was monitored using the Psoriasis Area and Severity Index (PASI) and Static Physician's Global Assessment (sPGA). Treatment-emergent adverse events (TEAEs) were summarized by treatment and racial and ethnic subgroup. Health-related quality of life was assessed using the Dermatology Life Quality Index (DLQI). RESULTS During the 12-week induction phase, 613 patients received ustekinumab (black, n = 20; Asian, n = 24; white, n = 551; Hispanic/Latino, n = 68) and 1236 patients received brodalumab 210 mg Q2W (black, n = 36; Asian, n = 39; white, n = 1116; Hispanic/Latino, n = 132). At week 52, a total of 590 patients received continuous ustekinumab (black, n = 19; Asian, n = 23; white, n = 532; Hispanic/Latino, n = 64) and 339 patients were re-randomized to continue receiving brodalumab 210 mg Q2W (black, n = 10; Asian, n = 7; white, n = 308; Hispanic/Latino, n = 40). Among patients who received brodalumab 210 mg Q2W, skin clearance response rates were similar across racial and ethnic subgroups at week 12 and week 52; rates of 75%, 90%, and 100% improvement in PASI from baseline were also higher, as was sPGA score ≤ 1, than in patients who received ustekinumab across all racial and ethnic subgroups. Rates of TEAEs and ≥ 5-point improvement in DLQI score were similar across racial and ethnic subgroups. CONCLUSIONS Brodalumab 210 mg Q2W is well tolerated and efficacious across diverse racial and ethnic subgroups in patients with psoriasis, including black, Asian, white, and Hispanic/Latino patients. TRIAL REGISTRY ClinicalTrials.gov identifier NCT01708603 (AMAGINE-2); NCT01708629 (AMAGINE-3).
Collapse
Affiliation(s)
- Amy McMichael
- Department of Dermatology, Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC, 27104, USA.
| | - Seemal R Desai
- Innovative Dermatology, Plano, TX, USA
- University of Texas Southwestern Medical Center, Dallas, TX, USA
| | | | | | - Andrew F Alexis
- Mount Sinai St. Luke's and Mount Sinai West, New York, NY, USA
| |
Collapse
|
31
|
Patel K, Rastogi S, Singam V, Lee H, Amin A, Silverberg J. Association between hidradenitis suppurativa and hospitalization for psychiatric disorders: a cross‐sectional analysis of the National Inpatient Sample. Br J Dermatol 2019; 181:275-281. [DOI: 10.1111/bjd.17416] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/08/2018] [Indexed: 01/05/2023]
Affiliation(s)
- K.R. Patel
- Department of Dermatology Northwestern University Feinberg School of Medicine Chicago IL 60611U.S.A
| | - S. Rastogi
- Department of Dermatology Northwestern University Feinberg School of Medicine Chicago IL 60611U.S.A
| | - V. Singam
- Department of Dermatology Northwestern University Feinberg School of Medicine Chicago IL 60611U.S.A
| | - H.H. Lee
- Department of Dermatology Northwestern University Feinberg School of Medicine Chicago IL 60611U.S.A
| | - A.Z. Amin
- Department of Dermatology Northwestern University Feinberg School of Medicine Chicago IL 60611U.S.A
| | - J.I. Silverberg
- Department of Dermatology, Preventive Medicine and Medical Social Sciences Northwestern University Feinberg School of Medicine Chicago IL 60611 U.S.A
- Northwestern Medicine Multidisciplinary Eczema Center Chicago IL U.S.A
| |
Collapse
|
32
|
Langley R, Armstrongi A, Lebwohl M, Blauvelt A, Hsu S, Tyring S, Rastogi S, Pillai R, Israel R. Brodalumab in patients who had inadequate response to ustekinumab. Br J Dermatol 2019. [DOI: 10.1111/bjd.17471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Langley R, Armstrongi A, Lebwohl M, Blauvelt A, Hsu S, Tyring S, Rastogi S, Pillai R, Israel R. Brodalumab 用于对乌司奴单抗应答不足的患者. Br J Dermatol 2019. [DOI: 10.1111/bjd.17484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
34
|
Singam V, Rastogi S, Patel KR, Lee HH, Silverberg JI. The mental health burden in acne vulgaris and rosacea: an analysis of the US National Inpatient Sample. Clin Exp Dermatol 2019; 44:766-772. [PMID: 30706514 DOI: 10.1111/ced.13919] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/19/2018] [Indexed: 11/27/2022]
Abstract
BACKGROUND Little is known about the mental health (MH) hospitalization among patients with acne and rosacea. AIMS To determine the MH disorders and cost burden associated with acne and rosacea. METHODS Data were examined from the 2002-2012 US National Inpatient Sample, comprising a sample of ~20% of all US paediatric and adult hospitalizations (n = 87 053 155 admissions). RESULTS A diagnosis of ≥ 1 MH disorder was much more common among all inpatients with vs. those without a diagnosis of acne (43.7% vs. 20.0%, respectively) and rosacea (35.1% vs. 20.0%, respectively). In multivariable logistic regression models controlling for sex, age, race/ethnicity and insurance status, acne (adjusted OR = 13.02; 95% CI 11.75-14.42) and rosacea (adjusted OR = 1.70; 95% CI 1.56-1.95) were associated with significantly higher odds of a primary admission for an MH disorder (13 and 8, respectively, of 15 MH disorders examined). Both acne and rosacea were associated with higher risk of mood, anxiety, impulse control and personality disorders, and with > $2 million of excess mean annual costs of hospitalization for MH disorders in the USA. CONCLUSION In this study, inpatients with acne or rosacea had increased odds of comorbid MH disorders. In particular, there was an increased number of hospital admissions secondary to a primary MH disorder with coexistent acne/rosacea. MH comorbidities were associated with considerable excess costs among inpatients with acne or rosacea.
Collapse
Affiliation(s)
- V Singam
- Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - S Rastogi
- Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - K R Patel
- Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - H H Lee
- Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - J I Silverberg
- Departments of Dermatology, Preventative Medicine, and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| |
Collapse
|
35
|
Noordzij GJ, van den Boomen YJG, Gilbert C, van Elk DJP, Roy M, Wilsens CHRM, Rastogi S. The aza-Michael reaction: towards semi-crystalline polymers from renewable itaconic acid and diamines. Polym Chem 2019. [DOI: 10.1039/c9py00463g] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
This paper reports, for the first time, semi-crystalline polymers based on bis-pyrrolidone dicarboxylic acids (BPDA) obtained from the aza-Michael reaction between renewable itaconic acid and various diamines.
Collapse
Affiliation(s)
- G. J. Noordzij
- Aachen-Maastricht Institute of Biobased Materials (AMIBM)
- Faculty of Science and Engineering
- Maastricht University
- 6167 RD Geleen
- The Netherlands
| | - Y. J. G. van den Boomen
- Aachen-Maastricht Institute of Biobased Materials (AMIBM)
- Faculty of Science and Engineering
- Maastricht University
- 6167 RD Geleen
- The Netherlands
| | - C. Gilbert
- Aachen-Maastricht Institute of Biobased Materials (AMIBM)
- Faculty of Science and Engineering
- Maastricht University
- 6167 RD Geleen
- The Netherlands
| | - D. J. P. van Elk
- Aachen-Maastricht Institute of Biobased Materials (AMIBM)
- Faculty of Science and Engineering
- Maastricht University
- 6167 RD Geleen
- The Netherlands
| | - M. Roy
- Aachen-Maastricht Institute of Biobased Materials (AMIBM)
- Faculty of Science and Engineering
- Maastricht University
- 6167 RD Geleen
- The Netherlands
| | - C. H. R. M. Wilsens
- Aachen-Maastricht Institute of Biobased Materials (AMIBM)
- Faculty of Science and Engineering
- Maastricht University
- 6167 RD Geleen
- The Netherlands
| | - S. Rastogi
- Aachen-Maastricht Institute of Biobased Materials (AMIBM)
- Faculty of Science and Engineering
- Maastricht University
- 6167 RD Geleen
- The Netherlands
| |
Collapse
|
36
|
Langley RG, Armstrong AW, Lebwohl MG, Blauvelt A, Hsu S, Tyring S, Rastogi S, Pillai R, Israel R. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. Br J Dermatol 2018; 180:306-314. [PMID: 30328108 DOI: 10.1111/bjd.17318] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/06/2018] [Indexed: 01/23/2023]
Abstract
BACKGROUND Brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, has demonstrated superior efficacy and safety over ustekinumab as induction therapy for moderate-to-severe psoriasis. OBJECTIVES To evaluate the efficacy and safety of brodalumab through week 52 in patients who had inadequate responses to ustekinumab. METHODS A subgroup analysis of the phase III AMAGINE-2/-3 double-blind randomized controlled trials was performed. Participants were aged 18-75 years and had a Psoriasis Area and Severity Index (PASI) ≥ 12, static Physician's Global Assessment score ≥ 3 and involvement of ≥ 10% body surface area. The studies were registered at ClinicalTrials.gov: AMAGINE-2, NCT01708603; AMAGINE-3, NCT01708629. RESULTS At baseline, patients with or without prior biologic experience who had an adequate response at week 16 on ustekinumab or brodalumab had lower rates of involved body surface area, PASI, prior biologic use, psoriatic arthritis and body mass index than patients who experienced inadequate response at or after week 16. Among patients who experienced inadequate response to ustekinumab, those rescued with brodalumab had PASI ≥ 75%, ≥ 90% and 100% improvement response rates of 72·6%, 58·1% and 36·3%, respectively, at week 52 compared with 61·7%, 25·5% and 5·4%, respectively, in patients who continued ustekinumab. Exposure-adjusted rates of treatment-emergent adverse events were similar among patients rescued with brodalumab (377·3 adverse events per 100 patient-years) and those who remained on ustekinumab (389·9 adverse events per 100 patient-years). CONCLUSIONS Among patients who experienced inadequate responses to ustekinumab, rescue with brodalumab improved skin clearance outcomes compared with continuing ustekinumab.
Collapse
Affiliation(s)
| | - A W Armstrong
- University of Southern California, Los Angeles, CA, U.S.A
| | - M G Lebwohl
- Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A
| | - A Blauvelt
- Oregon Medical Research Center, Portland, OR, U.S.A
| | - S Hsu
- Temple University School of Medicine, Philadelphia, PA, U.S.A
| | - S Tyring
- University of Texas Health Science Center, Houston, TX, U.S.A
| | - S Rastogi
- Ortho Dermatologics, Bridgewater, NJ, U.S.A
| | - R Pillai
- Dow Pharmaceutical Sciences, Petaluma, CA, U.S.A
| | - R Israel
- Valeant Pharmaceuticals North America LLC, Bridgewater, NJ, U.S.A
| |
Collapse
|
37
|
Dharmendra Kumar MG, Narayanan V, Manikandan R, Parameswaran A, Kumar P, Shree Ram Subba Reddy G, Rastogi S. Role of extra oral monofocal distractor device in the correction of the facial asymmetry, sleep apnoea, and quality of life associated with TMJ ankylosis. J Stomatol Oral Maxillofac Surg 2018; 120:203-210. [PMID: 30513389 DOI: 10.1016/j.jormas.2018.11.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/06/2018] [Revised: 10/31/2018] [Accepted: 11/25/2018] [Indexed: 10/27/2022]
Abstract
OBJECTIVES The purpose of this study is to evaluate the role of primary osteo-distraction prior to ankylosis release in patients, diagnosed with sleep apnoea, facial asymmetry, and reduced quality of life secondary to temporomandibular joint (TMJ) ankylosis. METHODS Ten patients in the age group of 13-40 years with TMJ ankylosis underwent primary osteo-distraction for mandibular advancement. They were evaluated pre- and post-operatively using radiographs, various questionnaires, and subjective evaluation of facial asymmetry, sleep apnoea, and quality of life (QOL). RESULTS All the ten patients showed significant improvement in their sleep apnoea symptoms with a mean of 6.20 ± 1.39 (P < 0.05). The mean advancement of the mandible in all the ten patients (both bilateral and unilateral ankylosis) was 15.8 mm (P < 0.05). The quality of life showed marked improvement from very poor to very satisfactory (P < 0.001). CONCLUSION Primary mandibular distraction is an effective method of correction of facial asymmetry, sleep apnoea, and quality of life in patients with TMJ ankylosis.
Collapse
Affiliation(s)
- M G Dharmendra Kumar
- Department of Oral and Maxillofacial Surgery, CKS Theja Dental College, Tirupati, Andhra Pradesh, India.
| | - V Narayanan
- Department of Oral and Maxillofacial Surgery, SRM Kattankulathur Dental College, India.
| | - R Manikandan
- Department of Oral and Maxillofacial Surgery, Meenakshi Ammal Dental College, India.
| | - A Parameswaran
- Department of Oral and Maxillofacial Surgery, Meenakshi Ammal Dental College. India.
| | - P Kumar
- Department of Oral and Maxillofacial Surgery, Sibar Dental College, India.
| | | | - S Rastogi
- Department of Oral and Maxillofacial Surgery, Kothiwal Dental College and Research Center, Moradabad, UP, India.
| |
Collapse
|
38
|
Patel K, Immaneni S, Singam V, Rastogi S, Silverberg J. A SYSTEMATIC REVIEW AND META-ANALYSIS OF DEPRESSION AND SUICIDE IN ATOPIC DERMATITIS. Ann Allergy Asthma Immunol 2018. [DOI: 10.1016/j.anai.2018.09.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
39
|
Friedman J, Rastogi S, Glaser L, Lis C, Carter I, Milad M. RCT: Tolerance of Chlorhexidine Gluconate versus Povidone-Iodine Vaginal Cleansing Solution. J Minim Invasive Gynecol 2018. [DOI: 10.1016/j.jmig.2018.09.184] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
40
|
Patel K, Singam V, Rastogi S, Lee H, Silverberg N, Silverberg J. Association of vitiligo with hospitalization for mental health disorders in
US
adults. J Eur Acad Dermatol Venereol 2018; 33:191-197. [DOI: 10.1111/jdv.15255] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2018] [Accepted: 09/05/2018] [Indexed: 12/20/2022]
Affiliation(s)
- K.R. Patel
- Department of Dermatology Northwestern University Feinberg School of Medicine Chicago IL USA
| | - V. Singam
- Department of Dermatology Northwestern University Feinberg School of Medicine Chicago IL USA
| | - S. Rastogi
- Department of Dermatology Northwestern University Feinberg School of Medicine Chicago IL USA
| | - H.H. Lee
- Department of Dermatology Northwestern University Feinberg School of Medicine Chicago IL USA
| | - N.B. Silverberg
- Department of Dermatology Mount Sinai Icahn School of Medicine New York NY USA
| | - J.I. Silverberg
- Department of Dermatology Northwestern University Feinberg School of Medicine Chicago IL USA
- Departments of Dermatology, Preventive Medicine and Medical Social Sciences Northwestern University Feinberg School of Medicine Chicago IL USA
| |
Collapse
|
41
|
Tiwari A, Rastogi S, Deo S, Sharma D, Sharma M, Bakshi S. Single arm prospective study evaluating the role of neoadjuvant chemotherapy in soft tissue sarcoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy299.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Chaudhuri S, Goel A, Awasthi A, Gupta S, Rastogi S, Panda D, Kumar N, Aneesh P. Disparity Between Metro-Centric Cancer Care and Rural Outreach in India: Situational Analysis and Future Trends in Context of Developing Countries. J Glob Oncol 2018. [DOI: 10.1200/jgo.18.86000] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Background: Radiation therapy is used in two-third of all patients diagnosed with cancer in any form and it has become an integral part of modern treatment strategies for many types of cancers in recent decade. Semi-urban and rural places in India lack healthcare facilities and so as the cancer care facilities. Aim: To identify the propensity of a metro-centric oncologic care in developing countries undermining the need of availability of facilities in smaller towns and cities. Methods: Data for state-wise population for 2016 and 2026 was projected using cohort component method. For the projection of cancer incidence and prevalence in 2016 and 2026, we assumed that the state-level prevalence and incidence of cancer in the year 2015 will not change over time in 2016. Data collected through telephonic interviews from the radiotherapy centers listed by Atomic Energy Regulatory Board (AERB), India. Further, we assumed few scenarios of cancer incidence and prevalence increase and projected state wise cancer burden in 2026. Results: With almost 70% population of India residing in districts and cities lacking quality health care, the situation of cancer care is much grave. India is currently equipped with only 394 RTU (Radiation Therapy Unit) against requirement of almost 1300 RTU, amounting to 0.38 RTU per million populations as per World Health Organization. The public sponsored healthcare infrastructure for cancer treatment, and research is centralized with all the resources centered in metro/major cities. Eight metro cities of India with a combined population of 140.6 million hold control of 188 RTU under their boundaries. Thus, while habitants of these eight metro cities, constituting only 10.9% of the national population, avail treatment benefit from 38% of total RTU capacity of India, rest of Indian population at 1143.8 million strengths is left prey to the wrath of cancer with just 306 machines at disposal. In comparison, the developed nations as the United States of America, Australia, and the United Kingdom fare far better in RTU availability for treatment of diagnosed cancer patients, with RTU per million population density of 12.45, 10.12 and 5.04 respectively. Similar scenario has been seen in other LMICs in world like Congo, Mongolia, Sudan, Nigeria, Nepal etc. Conclusion: We observed that wide disparity exists in India concerning RTU and cancer facility availability and density per million populations in between metro cities and rest of India and a dire need of improvement to fight against cancer which is very similar to the situation in developing countries.
Collapse
Affiliation(s)
| | - A. Goel
- Nayati Medicity, Oncology, Mathura, India
| | - A. Awasthi
- Nayati Medicity, Oncology, Mathura, India
| | - S.K. Gupta
- Nayati Medicity, Oncology, Mathura, India
| | - S. Rastogi
- Nayati Medicity, Oncology, Mathura, India
| | - D. Panda
- Nayati Medicity, Oncology, Mathura, India
| | - N. Kumar
- Nayati Medicity, Oncology, Mathura, India
| | - P. Aneesh
- Nayati Medicity, Oncology, Mathura, India
| |
Collapse
|
43
|
Patel K, Singam V, Vakharia P, Chopra R, Sacotte R, Rastogi S, Lee H, Patel N, Immaneni S, Kantor R, Hsu D, Silverberg J. LB1526 Comparison of DLQI, ItchyQOL, and 5-D itch scale for the assessment of the burden of atopic dermatitis in adults. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.06.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
44
|
Patel K, Singam V, Rastogi S, Lee H, Silverberg J. LB1502 Vitiligo is associated with multiple mental health disorders and psychiatric emergencies in the United States. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.06.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
45
|
Friedman J, Rastogi S, Glaser L, Lis C, Carter I, Milad M. RCT: tolerance of chlorhexidine gluconate versus povidone-iodine vaginal cleansing solution. Fertil Steril 2018. [DOI: 10.1016/j.fertnstert.2018.07.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Thiede R, Rastogi S, Nardone B, West D, Rangel S, Schlosser B. LB1516 Hyperkalemia in women with acne exposed to spironolactone in a large, urban, Midwestern U.S. population: A report from the Research on Adverse Drug Events and Reports Program (RADAR). J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.06.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
47
|
Singam V, Patel K, Lee H, Rastogi S, Silverberg J. LB1494 Alopecia areata is associated with a substantial mental health burden in US inpatients. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.06.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
48
|
Singam V, Orrell K, Patel K, Rastogi S, Kelm R, Rangel S, Laumann A, West D, Nardone B. LB1501 Chronic exposure to statin drugs and association with melanoma: A report from the RADAR (Research on Adverse Drug Events and Reports) project. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.06.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
49
|
Feldman SR, Rastogi S, Lin J. Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States. Dermatol Ther (Heidelb) 2018; 8:441-453. [PMID: 30006866 PMCID: PMC6109035 DOI: 10.1007/s13555-018-0251-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2018] [Indexed: 11/30/2022] Open
Abstract
Introduction Clinical trials have shown brodalumab to have better efficacy than ustekinumab for the treatment of moderate-to-severe psoriasis. An estimation of the cost-effectiveness of brodalumab vs. ustekinumab is warranted and may be useful for treatment decision-making processes, especially in the context of the cost considerations of the current US healthcare system. Therefore, we compared the cost-effectiveness of brodalumab with ustekinumab for treatment of moderate-to-severe psoriasis in biologic-naïve and biologic-experienced patients in the USA. Methods An Excel-based economic model was developed to estimate and compare total annual costs to health plans associated with treatment with brodalumab vs. ustekinumab per achievement of Psorasis Area and Severity Index (PASI) 75, 90, and 100 for patients with moderate-to-severe psoriasis. Results For treatment with brodalumab vs. ustekinumab, total annual treatment costs per PASI 75, 90, and 100 were $31,106, $57,776, and $163,069, respectively, lower for a patient naïve to prior biologic treatment; they were $40,535, $65,472, and $223,610, respectively, lower for a patient experienced with prior biologic treatment. In an additional analysis among patients with and without prior biologic failure, they were $52,822, $93,309, and $365,606, respectively, lower for a patient with failure and they were $31,660, $57,128, and $164,996, respectively, lower for a patient without failure. Conclusion Compared to ustekinumab, treatment with brodalumab was associated with better cost-effectiveness ratios for biologic-naïve and experienced-patients and also patients with and without prior biologic treatment failure. The greater cost-effectiveness of brodalumab was most prominent for biologic-experienced and prior biologic treatment failure patients. Funding Ortho Dermatologics.
Collapse
Affiliation(s)
- Steven R Feldman
- Wake Forest University School of Medicine, Winston-Salem, NC, USA.
| | | | - Jay Lin
- Novosys Health, Green Brook, NJ, USA
| |
Collapse
|
50
|
Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol 2018; 179:320-328. [PMID: 29488226 DOI: 10.1111/bjd.16464] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/08/2018] [Indexed: 01/16/2023]
Abstract
BACKGROUND Biologics are being used increasingly to treat moderate-to-severe psoriasis. Efficacy may differ in patients with previous exposure to biologics. OBJECTIVES To investigate the impact of previous biologic exposure on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis. METHODS Two placebo- and ustekinumab-controlled phase III clinical trials. There was an initial 12-week induction phase where patients were treated with brodalumab [210 mg or 140 mg every 2 weeks (Q2W)], ustekinumab or placebo. Efficacy end points included ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) and static Physician's Global Assessment (score of 0 or 1) vs. placebo, PASI 100 vs. ustekinumab, Dermatology Life Quality Index and Psoriasis Symptom Inventory. Adverse events were monitored throughout. RESULTS In total, 493 patients [334 (27%) brodalumab 210 mg Q2W and 159 (26%) ustekinumab] had received prior biologics; 150 (12%) and 62 (10%), respectively, reported previously failed treatment with a biologic. Brodalumab efficacy in patients with or without previous exposure to biologics was statistically equivalent: 40·9% and 39·5% of biologic-naive and -experienced patients achieved PASI 100 at week 12, compared with 21·1% and 17·0% with ustekinumab (both P < 0·001). In patients where prior biologics had been successful or failed, 41·7% and 32·0% achieved PASI 100, compared with 21·1% and 11·3% with ustekinumab. Tolerability was similar, and did not appear to be influenced by previous treatment with biologics. CONCLUSIONS The efficacy of brodalumab 210 mg Q2W was similar regardless of prior biological therapy (P = 0·31, 0·32 and 0·64 for PASI 75, 90 and 100, respectively). Almost twice as many patients achieved PASI 100 or complete clearance with brodalumab at week 12 compared with ustekinumab; the differences were most noticeable where previous biologics had failed. Both treatments were well tolerated.
Collapse
Affiliation(s)
- K A Papp
- Probity Medical Research, Waterloo, ON, Canada
| | - K B Gordon
- Medical College of Wisconsin, Milwaukee, WI, U.S.A
| | | | - M G Lebwohl
- Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A
| | - A B Gottlieb
- Department of Dermatology, New York Medical College, Metropolitan Hospital, New York, NY, U.S.A
| | - S Rastogi
- Valeant Pharmaceuticals North America LLC, Bridgewater, NJ, U.S.A
| | - R Pillai
- Dow Pharmaceutical Sciences (a division of Valeant Pharmaceuticals North America, LLC), Petaluma, CA, U.S.A
| | - R J Israel
- Valeant Pharmaceuticals North America LLC, Bridgewater, NJ, U.S.A
| |
Collapse
|